Cognita secures FDA breakthrough device designation for CXR
Cognita has received the US Food and Drug Administration (FDA) breakthrough device designation for the Chest X-Ray (CXR) model across…
All articles by Salong Debbarma
Salong Debbarma
-
-
Seqster unveils 1-Click DataLake for clinical trials
Seqster has launched 1-Click DataLake, a real-world data platform to expedite trial design, recruitment, and evidence generation for healthcare and…
-
Liberate Bio gains licences for myeloid-specific CAR design patents
Liberate Bio has obtained both exclusive and non-exclusive licences for patents related to chimeric antigen receptor (CAR) designs tailored for…
-
Philips launches Rembra CT system for acute imaging
Philips has unveiled its next-generation radiology computed tomography (CT) system, Rembra, to address the challenges faced by acute and high-demand…
-
HUTCHMED begins Phase I/IIa trial of HMPL-A580 for solid tumours
HUTCHMED has commenced a Phase I/IIa clinical trial of its second antibody-targeted therapy conjugate (ATTC), HMPL-A580, targeting patients with unresectable,…
-
Affinia receives FDA fast track designation for AFTX-201
Affinia Therapeutics has received the US Food and Drug Administration (FDA) fast track designation (FTD) for AFTX-201, a genetic medicine…
-
Droplet improves genomic analysis speed using NVIDIA Parabricks software
Droplet Biosciences has reported a reduction in genomic analysis turnaround time for residual cancer detection by adopting graphics processing unit…
-
Kyowa Kirin discontinues ongoing trials of rocatinlimab
Kyowa Kirin has announced the global discontinuation of all ongoing clinical trials for rocatinlimab, an anti-OX40 monoclonal antibody under investigation…
-
Esperion to acquire Corstasis for cardiovascular franchise expansion
Esperion Therapeutics has signed a definitive agreement to acquire Corstasis Therapeutics to expand its cardiovascular franchise with the addition of…
-
Roche’s Phase III trial of fenebrutinib in RMS meets primary endpoint
Roche has reported that the pivotal Phase III FENhance 1 trial of its investigational Bruton’s tyrosine kinase (BTK) inhibitor, fenebrutinib,…